Salvage chemotherapy in Hodgkin's disease. Results in patients relapsing more than twelve months after first complete remission.

Forty-nine patients with Hodgkin's disease who relapsed after a first complete remission of more than 12 months following primary chemotherapy were treated with salvage therapy regimens. A total of 41 patients (84%) achieved complete remission. In particular, complete response was documented in 17 of 19 patients re-treated with the same initial drug combination. The five-year freedom from progression, relapse-free and overall survivals were 51%, 57% and 65%, respectively. In our experience, consolidation radiotherapy following drug-induced remission failed to improve the five-year relapse-free survival. Present findings indicate that about half of patients relapsing after a disease-free interval exceeding 12 months can remain alive and disease-free 5 years after starting salvage chemotherapy.

[1]  L. Nadler,et al.  Autologous bone marrow transplantation in the treatment of malignant lymphoma and Hodgkin's disease. , 1988, Seminars in hematology.

[2]  S M Hubbard,et al.  The chemotherapy of lymphomas: looking back, moving forward--the Richard and Hinda Rosenthal Foundation award lecture. , 1987, Cancer research.

[3]  S. Rosenberg,et al.  Radiotherapy with curative intent: an option in selected patients relapsing after chemotherapy for advanced Hodgkin's disease. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  D. Rosenthal,et al.  Wide-field radiation therapy alone or with chemotherapy for Hodgkin's disease in relapse from combination chemotherapy. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  E. Jaffe,et al.  Twenty years of MOPP therapy for Hodgkin's disease. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  A. Santoro,et al.  Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results. , 1986, Annals of internal medicine.

[7]  A. Santoro,et al.  Third-line salvage chemotherapy in Hodgkin's disease. , 1985, Seminars in oncology.

[8]  S. Rosenberg,et al.  Late relapse among patients treated for Hodgkin's disease. , 1985, Annals of internal medicine.

[9]  S. Rosenberg,et al.  Combination chemotherapy for advanced Hodgkin's disease after failure of MOPP: ABVD and B-CAVe. , 1984, Annals of internal medicine.

[10]  F. Cabanillas,et al.  Long-term follow-up with ABDIC salvage chemotherapy of MOPP-resistant Hodgkin's disease. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  A. Santoro,et al.  ABVD chemotherapy in the treatment of Hodgkin's disease. , 1982, Cancer treatment reviews.

[12]  A. Santoro,et al.  Salvage chemotherapy with ABVD in MOPP-resistant Hodgkin's disease. , 1982, Annals of internal medicine.

[13]  J. Ultmann,et al.  Late relapses in hodgkin disease , 1981, American journal of hematology.

[14]  R. Fisher,et al.  Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse. , 1979, Annals of internal medicine.

[15]  E. Glatstein,et al.  Initial relapses in previously treated Hodgkin's disease. I. Results of second treatment , 1976, Cancer.

[16]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[17]  T. Miller,et al.  Radiation therapy salvage of Hodgkin's disease following chemotherapy failure. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  A. Santoro,et al.  Evolution in the treatment strategy of Hodgkin's disease. , 1982, Advances in cancer research.